Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

James Louis Januzzi Jr., M.D.

Co-Author

Back to Details
This page shows the publications co-authored by James Januzzi and Cian McCarthy.
James Januzzi
Connection Strength
17.836
Cian McCarthy
  1. Untangling Myocardial Injury: Moving From Consequence to Cause. J Am Coll Cardiol. 2021 Aug 24; 78(8):791-793.
    View in: PubMed
    Score: 0.980
  2. Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction. J Am Coll Cardiol. 2021 02 23; 77(7):848-857.
    View in: PubMed
    Score: 0.947
  3. Increasingly Sensitive Troponin Assays: Is Perfect the Enemy of Good? J Am Heart Assoc. 2020 12; 9(23):e019678.
    View in: PubMed
    Score: 0.931
  4. Derivation and External Validation of a High-Sensitivity Cardiac Troponin-Based Proteomic Model to Predict the Presence of Obstructive Coronary Artery Disease. J Am Heart Assoc. 2020 08 18; 9(16):e017221.
    View in: PubMed
    Score: 0.912
  5. Cardiac Troponin and the True False Positive. JACC Case Rep. 2020 Mar; 2(3):461-463.
    View in: PubMed
    Score: 0.888
  6. Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays: A Practical Approach for Clinicians. JAMA Cardiol. 2019 10 01; 4(10):1034-1042.
    View in: PubMed
    Score: 0.860
  7. Passivating High-Risk Plaques: Try, Try Again. JACC Cardiovasc Imaging. 2020 07; 13(7):1561-1563.
    View in: PubMed
    Score: 0.852
  8. Trivializing an Elevated Troponin: Adding Insult to Injury? J Am Coll Cardiol. 2019 01 08; 73(1):10-12.
    View in: PubMed
    Score: 0.817
  9. Type 2 Myocardial Infarction and the Hospital Readmission Reduction Program. J Am Coll Cardiol. 2018 09 04; 72(10):1166-1170.
    View in: PubMed
    Score: 0.798
  10. Type 2 Myocardial Infarction-Diagnosis, Prognosis, and Treatment. JAMA. 2018 Aug 07; 320(5):433-434.
    View in: PubMed
    Score: 0.794
  11. A clinical and proteomics approach to predict the presence of obstructive peripheral arterial disease: From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study. Clin Cardiol. 2018 Jul; 41(7):903-909.
    View in: PubMed
    Score: 0.786
  12. Single-Molecule Counting of High-Sensitivity Troponin I in Patients Referred for Diagnostic Angiography: Results From the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) Study. J Am Heart Assoc. 2018 03 08; 7(6).
    View in: PubMed
    Score: 0.771
  13. Evaluating Chest Pain in the Emergency Department: Searching for the Optimal Gatekeeper. J Am Coll Cardiol. 2018 02 13; 71(6):617-619.
    View in: PubMed
    Score: 0.768
  14. Soluble ST2 in Heart Failure. Heart Fail Clin. 2018 Jan; 14(1):41-48.
    View in: PubMed
    Score: 0.762
  15. Biomarkers in stable coronary artery disease. Am Heart J. 2018 02; 196:82-96.
    View in: PubMed
    Score: 0.752
  16. Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study). Am J Cardiol. 2017 07 01; 120(1):25-32.
    View in: PubMed
    Score: 0.724
  17. Hospitalizations and Outcomes of T1MI Observed Before and After the Introduction of MI Subtype Codes. J Am Coll Cardiol. 2021 Sep 21; 78(12):1242-1253.
    View in: PubMed
    Score: 0.246
  18. The Intersection of Type 2 Myocardial Infarction and Heart Failure. J Am Heart Assoc. 2021 09 07; 10(17):e020849.
    View in: PubMed
    Score: 0.245
  19. A Test in Context: Interpretation of High-Sensitivity Cardiac Troponin Assays in Different Clinical Settings. J Am Coll Cardiol. 2021 03 16; 77(10):1357-1367.
    View in: PubMed
    Score: 0.238
  20. Cardiologist Evaluation of Patients With Type 2 Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2021 01; 14(1):e007440.
    View in: PubMed
    Score: 0.232
  21. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. EClinicalMedicine. 2020 Sep; 26:100504.
    View in: PubMed
    Score: 0.228
  22. Home-Time After Discharge Among Patients With Type 2 Myocardial Infarction. J Am Heart Assoc. 2020 05 18; 9(10):e015978.
    View in: PubMed
    Score: 0.224
  23. Inflammation in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 03 24; 75(11):1324-1340.
    View in: PubMed
    Score: 0.222
  24. Sex Differences in Patient Characteristics, Treatment Strategies, and Outcomes for Type 2 Myocardial Infarction. J Am Coll Cardiol. 2019 06 25; 73(24):3230-3232.
    View in: PubMed
    Score: 0.211
  25. Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death. J Am Coll Cardiol. 2019 05 07; 73(17):2135-2145.
    View in: PubMed
    Score: 0.209
  26. Misclassification of Myocardial Injury as Myocardial Infarction: Implications for Assessing Outcomes in Value-Based Programs. JAMA Cardiol. 2019 05 01; 4(5):460-464.
    View in: PubMed
    Score: 0.209
  27. Association of the New Peer Group-Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. JAMA Netw Open. 2019 04 05; 2(4):e192987.
    View in: PubMed
    Score: 0.208
  28. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. J Am Coll Cardiol. 2019 03 26; 73(11):1273-1284.
    View in: PubMed
    Score: 0.207
  29. Left Ventricular Thrombus: Contemporary Etiologies, Treatment Strategies, and Outcomes. J Am Coll Cardiol. 2019 04 23; 73(15):2007-2009.
    View in: PubMed
    Score: 0.206
  30. Underutilization of Cardiac Rehabilitation for Type 2 Myocardial Infarction. J Am Coll Cardiol. 2019 04 23; 73(15):2005-2007.
    View in: PubMed
    Score: 0.206
  31. A clinical, proteomics, and artificial intelligence-driven model to predict acute kidney injury in patients undergoing coronary angiography. Clin Cardiol. 2019 Feb; 42(2):292-298.
    View in: PubMed
    Score: 0.204
  32. Blood kidney injury molecule-1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography-Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. Am Heart J. 2019 03; 209:36-46.
    View in: PubMed
    Score: 0.203
  33. Multiple biomarker panel to screen for severe aortic stenosis: results from the CASABLANCA study. Open Heart. 2018; 5(2):e000916.
    View in: PubMed
    Score: 0.202
  34. Endothelin-1 Measurement in Patients Undergoing Diagnostic Coronary Angiography-Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study. Clin Chem. 2018 11; 64(11):1617-1625.
    View in: PubMed
    Score: 0.200
  35. Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment. JAMA Cardiol. 2018 07 01; 3(7):642-649.
    View in: PubMed
    Score: 0.197
  36. Type 2 Myocardial Infarction - An Evolving Entity. Circ J. 2018 01 25; 82(2):309-315.
    View in: PubMed
    Score: 0.191
  37. Application of the GRACE, TIMI, and TARRACO Risk Scores in Type 2 Myocardial Infarction. J Am Coll Cardiol. 2020 01 28; 75(3):344-345.
    View in: PubMed
    Score: 0.054
  38. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. J Am Coll Cardiol. 2019 04 02; 73(12):1596-1598.
    View in: PubMed
    Score: 0.052
  39. Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. J Am Coll Cardiol. 2018 12 25; 72(25):3370-3372.
    View in: PubMed
    Score: 0.051
  40. Delirium in the Cardiac Intensive Care Unit. J Am Heart Assoc. 2018 02 16; 7(4).
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.